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ABSTRACT
Introduction: This study will develop the first human
challenge model of paratyphoid infection which may
then be taken forward to evaluate paratyphoid vaccine
candidates. Salmonella Paratyphi A is believed to cause
a quarter of the estimated 20 million cases of enteric
fever annually. Epidemiological evidence also suggests
that an increasing proportion of the enteric fever
burden is attributable to S. Paratyphi infection meriting
further attention and interest in vaccine development.
Assessment of paratyphoid vaccine efficacy in
preclinical studies is complicated by the lack of a small
animal model and the human-restricted nature of the
infection. The use of experimental human infection in
healthy volunteers provides an opportunity to address
these problems in a cost-effective manner.
Methods and analysis: Volunteers will ingest
virulent S. Paratyphi A bacteria (NVGH308 strain) with
a bicarbonate buffer solution to establish the infectious
dose resulting in an ‘attack rate’ of 60–75%. Using an
a priori decision-making algorithm, the challenge dose
will be escalated or de-escalated to achieve the target
attack rate, with the aim of reaching the study end
point while exposing as few individuals as possible to
infection. The attack rate will be determined by the
proportion of paratyphoid infection in groups of 20
healthy adult volunteers, with infection being defined
by one or more positive blood cultures
(microbiological end point) and/or fever, defined as an
oral temperature exceeding 38°C sustained for at least
12 h (clinical end point); 20–80 participants will be
required. Challenge participants will start a 2-week
course of an oral antibiotic on diagnosis of infection,
or after 14 days follow-up.
Ethics and dissemination: The strict eligibility
criterion aims to minimise risk to participants and
their close contacts. Ethical approval has been
obtained. The results will be disseminated in a
peer-reviewed journal and presented at international
congresses.
Trial registration number: NCT02100397.
INTRODUCTION
Enteric fever is the term used to describe
systemic illness caused by infection with
Salmonella enterica serovars Typhi and Paratyphi
A and C. Enteric fever is a leading cause
of morbidity worldwide, particularly among
young, school-aged children in resource-
limited settings and increasingly among travel-
lers to those areas.1 2
While infection with S. Typhi accounts for
the majority of enteric fever cases, the
proportion of disease caused by S. Paratyphi
A is increasing, particularly in the highly
endemic regions of Southeast Asia and the
Indian subcontinent.3 As a human-restricted
pathogen, the targeted vaccination of those
groups at high risk is likely to have a substan-
tial impact on disease incidence.4
Strengths and limitations of this study
▪ The development of a Salmonella Paratyphi human
challenge model should expedite the development
and evaluation of potential paratyphoid vaccine
candidates, in particular by allowing the direct
measurement of vaccine protective efficacy in a
safe, reproducible host-relevant model.
▪ Studying the longitudinal physiological and
immunological responses to infection will provide
insight into this increasingly prevalent but poorly
understood infection.
▪ The modest number of participants in challenge
studies can make the model sensitive to individ-
ual variation.
▪ The response to challenge may not reflect the
target population who may have protection due
to repeated natural exposure.
▪ The immunobiological response to S. Paratyphi
A exposure may differ between strains.
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In view of the high burden of enteric fever and
increasing antibiotic resistance, the WHO has stated that
countries with high-risk groups and populations ‘should
consider the programmatic use of typhoid vaccines for
controlling endemic disease’.4 Despite this recommen-
dation, there has been a reluctance to introduce pro-
grammes with the available licensed typhoid vaccines,
Vi polysaccharide (ViPS) and Ty21a, as both have
limited efﬁcacy, offer minimal cross-protection against
paratyphoid infection, and cannot be given to children
less than 2 years of age. This has focused development
on ﬁrstly conjugate S. Typhi and Paratyphi A vaccines,
which can be administered to infants and expected to
provide long-lasting immune memory, as well as attenu-
ated oral vaccines.5 6 A number of promising candidate
vaccines are in early phase testing.5–8
The aim of this study is to develop a safe, reliable
human paratyphoid challenge model in which to valid-
ate vaccines and develop novel diagnostics. Human chal-
lenge studies with S. Typhi (Quailes strain) have been
performed historically and recently using an adapted
model.9–11 To the best of our knowledge, human chal-
lenge with virulent S. Paratyphi has not been performed
previously, so this study will provide a unique opportun-
ity to study human paratyphoid infection. The study is
designed to determine the dose of S. Paratyphi A (chal-
lenge strain NVGH308) required to produce an infec-
tion attack rate of 60–75% in healthy adult volunteers
who have not previously been exposed to typhoidal sal-
monella and are therefore immunologically naive to the
challenge agent. With sufﬁcient evidence of paratyphoid
infection at a target dose, this model can then be taken
forward to evaluate paratyphoid vaccine candidates.
METHODS/DESIGN
This is a descriptive, dose-level escalation human infec-
tion study using the S. Paratyphi A challenge of ambula-
tory, outpatient healthy community adult volunteers. For
safety, the study will start with the challenge of one indi-
vidual at an initial dose of 1–5×103 colony forming units
(CFU). Consecutive groups of 5 or 10 participants will
then be challenged a minimum of 2 weeks apart follow-
ing a decision-making algorithm for dose escalation/
de-escalation (see ﬁgure 1). This algorithm was used for
the typhoid challenge model developed by the
University of Oxford in 2009.9
Regulation and governance
In the UK, investigational products, such as unlicensed
medications and vaccines, are regulated by the
Medicines for Human Use (Clinical Trials) Regulations
2004 which implement the European Clinical Trials
Directive (2001/20/EC).12 However, most microbial
challenge studies fall outside the remit of the European
Clinical Trials Directive (ECTD) and are instead judged
according to common law and best practice.13 The
typhoid and paratyphoid challenge models, using a fully
characterised and non-genetically modiﬁed strain, falls
under this category. To achieve best practice, challenge
protocols undergo independent and rigorous peer
review to assess the scientiﬁc quality and appropriateness
of the study methodology to answer the key objectives.
This includes conforming to Good Clinical Practice
(GCP) guidelines with support from a research ethics
committee experienced in these studies.14 As such, local
or regional ethics committees, independent of the
researchers and sponsors, are fundamental for research
governance of microbial challenge studies.
Challenge strain
The original S. Paratyphi A strain NVGH308 was isolated
in 2006 from a patient with acute paratyphoid fever as part
of a study performed by the Oxford University Clinical
Research Unit at Patan Hospital, Kathmandu, Nepal. It
has been manufactured to Good Manufacturing Practice
(GMP) standard and is supplied for study purposes by
Novartis Vaccines for Global Health, Italy. Manufacturing
to GMP standard, while not a regulatory requirement in
the UK, fulﬁls best practice.13
A parent seed lot, S888P5SP01, was established in
March 2010 after serial colony selections on Luria Broth
PTK agar plates and stored in the Novartis Vaccines and
Diagnostics bacterial seed bank (Siena, Italy). This seed
lot underwent ﬁve sequential passages as part of the cell
line cleaning process before being used to establish the
GMP Master Cell Bank, SA-13-002, of the NVGH308
strain. GenIbet BioPharmaceuticals (Oeiras, Portugal)
produced three dose levels of the challenge agent under
GMP conditions. Prepared vials containing the chal-
lenge agent were stored at −80°C±5°C and transferred
via an accredited courier to the Oxford Vaccine Group
Laboratory in 2013.
Batch testing of the cell bank conﬁrms O:1 and O:2
antigen positivity, batch purity and stable viable bacterial
count. Ongoing stability testing of the seed lot has been
performed by Novartis Vaccines and Diagnostics. The
NVGH308 strain is fully characterised with known
susceptibility to a number of antimicrobial options.
Study objectives
The primary objective is to determine the dose
(in CFU) of S. Paratyphi A, challenge strain NVGH308,
needed to produce a 60–75% attack rate when ingested
with sodium bicarbonate solution by healthy adult
volunteers. The secondary objectives will describe the
interaction between bacteria and human host at base-
line, through inoculation and symptomatic infection
(or asymptomatic immune protection) to recovery and
long-term follow-up (see table 1).
Feedback and recommendations from Patient and
Public Involvement (PPI), in addition to participant
questionnaires from previous studies, have been incorpo-
rated into this study. This beneﬁcial process will con-
tinue with an anonymous questionnaire to be completed
by participants 28 days after challenge.
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The questionnaire will be closely based on the one
used by the Oxford Vaccine Group (OVG) in previous
typhoid studies to explore participants’ study experience.
This includes motivations, attitudes and factors inﬂuen-
cing participation in human challenge research, as well
as their experience of study procedures such as ingesting
the challenge agent.
Study setting
The study will be conducted at the Centre for Clinical
Vaccinology and Tropical Medicine, Oxford, UK, which
is a fully equipped vaccine research site with available
clinical inpatient facilities and a Category III level
laboratory on-site. The UK is non-endemic for enteric
fever with the majority of cases travel related; the rate of
paratyphoid fever notiﬁcation in the Thames Valley
region, which includes Oxfordshire, is 0.5/100 000.15
Recruitment
Several strategies may be employed in order to recruit
the required cohort of volunteers. These include:
▸ Study invitation letters with reply slips, sent out by the
National Health Applications and Infrastructure
Services who hold the central National Health
Services (NHS) patient database (Open Exeter),
▸ Website and poster advertising,
▸ Direct mail-out using the Electoral register,
▸ Email communication to local tertiary education
facilities.
The Oxford Vaccine Centre also manages a secure
database for healthy volunteers who have expressed an
interest in being contacted about potential studies.
Potential participants will be invited for a screening and
consent visit, where a member of the clinical team will
assess their eligibility.
Participants will be offered reimbursement for their
time, travel and inconvenience. The amount, frequency
and method of payment will be described in the study
information booklet. The payment schedule will hope-
fully encourage attendance of follow-up appointments.
Eligibility criteria
Male or female participants, aged 18–60 years inclusive,
who are in good health (as determined by a study
doctor, medical investigation and agreement by their
general practitioner) and able to provide written
informed consent, will be eligible for inclusion in this
study. Additional inclusion and exclusion criteria will be
applied to ensure that participants are appropriate for
the study (see online supplementary 1). This includes a
participant’s ability to attend daily appointments for
2 weeks after challenge with S. Paratyphi A. These strict
criteria aim to minimise the risk of severe or compli-
cated disease in participants and reduce the potential
risk of transmission to close contacts.
Interventions
A participant will be considered enrolled in the study on
their day of challenge.
Figure 1 Decision-making algorithm for Salmonella Paratyphi dose escalation/de-escalation, starting at 1–5×103, to reach the
primary end point (pts, patients).
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The method used for preparation of the challenge
inocula is based on the one used for the recent typhoid
challenge model.9 Participants will fast for 90 min before
ingesting 120 mL of sodium bicarbonate (2.1 g
NaHCO3) to neutralise stomach acid. This is followed
60 s later by the challenge inocula which will be freshly
prepared prior to each challenge by defrosting and sus-
pending the required bacterial dose in 30 mL of sodium
bicarbonate (0.53 g NaHCO3).
After S. Paratyphi A ingestion, participants will be seen
daily for 14 days with blood, stool, saliva and urine
samples taken at set time points (see online supplemen-
tary 2). Monitoring for derangement of liver, renal,
blood count parameters and inﬂammatory markers will
be performed. Participants will also complete twice-daily
temperature readings and record any symptoms experi-
enced for 21 days; these data will be collected by elec-
tronic case report forms (eCRFs) and diary cards.
Subsequent follow-up appointments will be 28, 90, 180
and 365 days after challenge (ﬁgure 2).
Paratyphoid infection will be diagnosed after chal-
lenge if one of the following applies:
▸ A positive blood culture for S. Paratyphi from 72 h
after challenge,
▸ A positive blood culture for S. Paratyphi within 72 h,
with one or more signs/symptoms of paratyphoid
infection,
▸ Persistent positive blood cultures for S. Paratyphi
within 72 h,
▸ An oral temperature>38°C persisting for 12 h.
The earliest microbiological indication that a partici-
pant has an S. Paratyphi A bacteraemia will be the iden-
tiﬁcation of a Gram-negative bacillus (GNB) from a
positive blood culture. As formal identiﬁcation of the
organism may take a minimum of a further 24 h, partici-
pants in whom a GNB is identiﬁed will be deﬁned as
having paratyphoid fever.
Ciproﬂoxacin 500 mg twice daily for 14 days will start
on diagnosis of paratyphoid infection or at day 14 after
challenge. The rationale for using ﬂuoroquinolones as a
Table 1 Study objectives and outcomes
Objective(s) Outcome/end point(s)
Primary To determine the dose (in colony forming units) of
Salmonella Paratyphi A, challenge strain NVGH308,
needed to produce a 60–75% attack rate when ingested
with sodium bicarbonate solution in healthy adult
volunteers
Clinically or microbiologically proven paratyphoid
infection following oral challenge with S. Paratyphi A,
strain NVGH308, delivered with sodium bicarbonate
solution
Secondary (1) To describe the human physiological response to
S. Paratyphi A challenge, and in those developing or
not developing infection
Description of the clinical course after challenge
using, for example, participant symptom profiles,
temperature measurements and other recorded
clinical and laboratory observations
(2) To evaluate the sensitivity of the predefined criteria
for paratyphoid infection, using subsequent clinical,
microbiological and laboratory outcomes
Determination of the challenge dose/kg (dose/
surface area) actually ingested by those developing
and those not developing paratyphoid infection at
each dose level.
Analysis of the attack rate using alternative criteria
including, for example, passive field surveillance
definitions, alternative temperature thresholds and
adjunctive microbiological and laboratory diagnostic
assays
(3) To describe the characteristics of bacterial dynamics
after challenge, including onset and duration of
bacteraemia, bacterial burden at diagnosis and stool
shedding
Microbiological assays to detect and characterise
S. Paratyphi after challenge in blood, stool and urine
(4) To describe the human immune response to
challenge, including the innate, humoral,
cell-mediated and mucosal responses
Immunological laboratory assays to measure innate,
humoral, cell-mediated and mucosal responses to
challenge
(5) To determine genetic features affecting host–
pathogen responses, alteration of those responses
through epigenetic changes, control of gene
expression and post-translational modifications
Laboratory and high-throughput assays to measure
genetic factors affecting susceptibility, gene
expression and protein translation
(6) To discover, develop and evaluate novel diagnostic
methods for S. Paratyphi A infection
Exploratory analysis of blood, faeces, saliva and
urine samples using experimental assays and
diagnostics
(7) To explore the factors, influences and motivation
affecting volunteers’ decision to participate in human
challenge studies and their experiences of the study
process
Participant responses using questionnaires during
the course of the study
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ﬁrst-line agents is based on recommendations for treat-
ment of enteric fever and prevention (and treatment) of
chronic gallbladder carriage as therapeutic levels are
reached in bile and gallbladder.16 17 All positive blood
culture isolates will have full susceptibility proﬁling
performed using an antibiotic disc method and Etest
to measure the ciproﬂoxacin minimum inhibitory con-
centration (MIC). Alternative antibiotics used as second-
line therapy (in the event of adverse reactions or side
effects) include azithromycin and trimethoprim/
sulfamethoxazole.
If the participant’s symptoms fail to resolve after anti-
biotic administration, if they are unable to tolerate oral
antibiotics, become dehydrated, or if unanticipated con-
cerns regarding home circumstances emerge, inpatient
admission to an infectious diseases unit will be consid-
ered. Patient care at this stage would be delegated to the
hospital clinical team, which could include the provision
of intravenous ﬂuids, antibiotics and antiemetics.
Safety
Participant safety during the study: Participants will be mon-
itored closely with daily clinical review and completion
of symptom diary cards. All adverse events will be
recorded on CRFs, with serious events notiﬁed to the
Data Safety Monitoring Committee (DSMC) within 24 h
of the investigator becoming aware of the event. Adverse
events of special interest (AESI) will also be reported to
the DSMC in the same manner and include:
▸ Complications of paratyphoid fever such as perfor-
ation or haemorrhage which occurs almost exclusively
in patients who are untreated for an extended
period,18
▸ Failure to clinically or bacteriologically cure a partici-
pant of acute paratyphoid infection within 14 days of
antibiotic therapy,
▸ Relapse or progression to carrier state, the latter
deﬁned as a person who is still excreting S. Paratyphi
A after two courses of appropriate antibiotic therapy,19
▸ Transmission of S. Paratyphi to non-study participants.
The DSMC for this study will be composed of an inde-
pendent and trial-experienced group of infectious
disease and public health clinicians and a statistician.
Safety data collated from eCRFs and eDiaries, which
include blood parameters, vital signs and symptom
recordings, will be reviewed by the DSMC after the ﬁrst
participant has been challenged and at each dose escal-
ation. Approval from the DSMC will be required prior to
any subsequent dose alterations. This role and function
of the DSMC will be described in a Charter, agreed
prior to the start of recruitment.
Long-term safety of participants: The risk of chronic
carriage with S. Paratyphi A is minimised by treatment for
2 weeks with an effective antibiotic and excluding partici-
pants with gallbladder disease.20 In addition,
stool samples for culture will be obtained 2 weeks after
completion of the antibiotic course and then weekly until
two successive samples are negative. If samples remain
positive for S. Paratyphi A 4 weeks after completion of
antibiotics, then the participant will be referred to a NHS
infectious diseases consultant for further management.
Safety of non-study participants: The risk of secondary
transmission to close contacts is unlikely in view of the
low infectivity of S. Paratyphi A and the level of hygiene
and sanitation in the UK.21 Consent will not be obtained
from close household contacts, but participants will be
required to provide them with a written study summary
detailing measures to reduce the risk of infection and
offering screening for paratyphoid infection. Even in the
absence of transmission precautions, the rate of second-
ary cases is exceptionally low within the UK.22
The participants will consent to the clinical study team
informing the local Health Protection Unit of their
involvement in the study. The Unit will be notiﬁed of
their challenge date and when stool clearance has been
completed. Any breach in enteric hygiene precautions
that result in another individual coming into contact
with infectious material will be reported, with potential
cases of transmission to be conﬁrmed by sequence com-
parison to an isolate of the challenge strain stored at a
Public Health England microbiology reference labora-
tory (Colindale, London).
Sample size
The selected sample size balances the need for a statis-
tically reproducible attack rate while minimising the
number of individuals exposed to paratyphoid infection.
To meet the primary objective of a clinically reprodu-
cible attack rate of 60–75%, this careful, dose (de-)escal-
ation protocol will be followed.9 The maximum number
of participants required will be 80, with the minimum 20
if the starting dose (1–5×103 CFU) satisﬁes our criteria.
This is based on the probability that the criteria are satis-
ﬁed according to the true attack rate.
If the attack rate in the ﬁrst group of 20 participants is
greater than 75%, a lower dose will be decided based on
the prior attack rate combined with laboratory and clin-
ical ﬁndings. De-escalation to a dose lower than 1–5×103
CFU will also be considered if the target attack rate is
reached and the chief investigator, with agreement from
the DSMC, decides that a lower dose may achieve a
similar attack rate.
Statistical analysis
The analysis of the primary end point will be descriptive
only. The percentage of participants who meet the cri-
teria for diagnosis of paratyphoid will be calculated with
a 95% Clopper-Pearson Exact CI. Those individuals who
withdraw or are treated prior to day 14 without prior
diagnosis of paratyphoid would be excluded from this
analysis. A secondary analysis of the primary end point
will be conducted using the Kaplan-Meier method
which will include all participants.
Time-to-event analyses of individual components of
the primary outcome (eg, positive blood culture for
S. Paratyphi, oral temperature>38.0°C, etc) will be
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conducted using the Kaplan-Meier method and will
include all participants. Participants not meeting the cri-
teria for an individual component of the primary end
point will be censored in the analysis at the time of diag-
nosis or at day 14 for those undiagnosed.
DISCUSSION
This will be the ﬁrst S. Paratyphi A human challenge
model developed. It is presumed that this study will be
similar to the experience of recent typhoid challenge
studies based on the literature iterating the similar
clinical presentation between typhoid and paratyphoid
fever.9 23 24 Clinical knowledge, however, of the
NVGH308 paratyphoid A strain is limited to details from
the original patient, in contrast to the S. Typhi Quailes
strain where data from 762 challenged participants from
the 1960s informed the re-establishment of a typhoid
challenge model in 2009.25 While the lowest infective
inoculum of S. Paratyphi A is unknown, it is believed to
be similar to or higher than S. Typhi.26 27 As such, we
will use the same starting dose of 103 CFU that was used
in the 2009 typhoid challenge model. This dose was the
highest dose of S. Typhi that did not cause clinical infec-
tion in the historical typhoid challenge studies.28 When
coadministered with the sodium bicarbonate solution,
103 CFU S. Typhi (Quailes strain) gave an attack rate of
55%, necessitating a dose escalation to reach the target
attack rate of 60–75%.9 We anticipate that the same will
occur with the S. Paratyphi A challenge.
The outpatient management of participants chal-
lenged with typhoid is safe and achievable; this has been
Figure 2 Participant journey through the study.
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key in re-establishing the challenge model due to the
prohibitive cost of inpatient care.9 Participant satisfac-
tion with this model, plus the monetary reimbursement
for their time, travel expenses, blood draws and poten-
tial days off work, is high.29
The modest number of participants in challenge
studies can make the model sensitive to individual vari-
ation. Selecting an antigen-naive cohort limits this vari-
ation, but the response may not reﬂect the target
population who may have protection due to repeated
natural exposure, with consequent overestimation of the
potential efﬁcacy of a candidate vaccine.30 Conversely,
the challenge dose required to achieve a sufﬁciently
high attack rate within a manageable 2-week period is
likely to be higher than was encountered in the ﬁeld.
This may overwhelm candidate vaccines with errone-
ously discouraging protective efﬁcacy, as was seen in the
Maryland typhoid studies.31
The NVGH308 strain, while originally a clinical isolate,
may not be representative of the current circulating
strains in endemic settings. S. Paratyphi A, however, is a
clonal monomorphic pathogen containing limited
genomic variation,32 33 making it likely that the pathogen-
icity and immune response to the NVGH308 S. Paratyphi
A challenge will translate to wild-type strains and that
future vaccines will provide cross-strain protection.
Current promising candidate S. Paratyphi vaccines are
based on whole cell live-attenuated strains or subunit
approaches that conjugate O polysaccharide (O:2) to a
range of protein carriers. This O:2 polysaccharide antigen
of S. Paratyphi A is known to play a role in protection and
virulence.34 A phase II trial is underway of O:2 conjugated
to tetanus toxoid (O:2-TT), conducted after initial trials
showed that it was safe and immunogenic.5 A second con-
jugate vaccine moving into clinical testing is O:2 conju-
gated to CRM197 (O:2-CRM197), which demonstrated
immunogenicity in preclinical studies with strong bacteri-
cidal activity against S. Paratyphi A when developed alone
or in combination with Vi-CRM197.
7 A live-attenuated oral
vaccine candidate (Centre for Vaccine Development
(CVD) 1901, University of Maryland) has also been shown
to be well tolerated and immunogenic in phase I trials and
further phase I studies are ongoing.8
Although promising vaccines are in development, it is
a long and costly process for any vaccine to get to licen-
sure. The lack of a reliable correlate of protection and
the poorly understood immunobiology of typhoid and
paratyphoid infection adds to the difﬁculties in enteric
fever vaccine development. Equally, highly sensitive
and speciﬁc diagnostic tests for use in endemic settings
are needed, but their development and, particularly, val-
idation has been hindered by the lack of a patient
cohort immunologically naive to typhoidal salmonella.
Advancing knowledge on the microbiological and
human–host response to exposure is necessary to inform
transmission and impact modelling for vaccine roll-out,
key for targeted vaccination programmes of high-risk
population groups.
The development of an S. Paratyphi A human challenge
model could help overcome some of these limitations. As
trials for paratyphoid and bivalent vaccine candidates are
approaching Phase I/II stages, a paratyphoid challenge
model could provide a crucial intermediate step in pro-
gressing efﬁcacious vaccine candidates into more expan-
sive ﬁeld trials in endemic settings. Ideally, this will be
translated into rapid, cost-effective diagnostics, contribut-
ing to the disease surveillance necessary for vaccination
programmes. Future measures to control enteric fever are
expected to combine an effective bivalent vaccine against
both serovars with public health measures that improve
sanitation and access to clean water.
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